Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

QUIREDEX: A National, Open-Label, Multicenter, Randomized, Phase III Study of Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression

NCT00480363 is registered in ClinicalTrials.gov with PETHEMA Foundation as lead sponsor.

NCT NCT00480363
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00480363 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
QUIREDEX: A National, Open-Label, Multicenter, Randomized, Phase III Study of Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression
Lead sponsor
PETHEMA Foundation
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2007
Completion date
July 31, 2013
Enrollment
120 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma